Emerging fungal infections in immunocompromised patients

Invasive fungal infections are infections of importance and are increasing in incidence in immunocompromised hosts such as patients who have had hematopoietic stem cell and solid organ transplants. Despite our expanded antifungal armamentarium, these infections cause considerable morbidity and mortality. Indeed, certain trends have emerged in these invasive fungal infections: a rise in the incidence of invasive mold infections, an increase in the non-albicans strains of Candida spp. causing invasive disease and, finally, the emergence of less susceptible fungal strains that are resistant to the broader-spectrum antifungal agents due to overutilization of these agents. Clinicians must recognize the patient groups that are potentially at risk for these invasive fungal infections, as well as the risk factors for such infections. By using more sensitive nonculture-based diagnostic techniques, appropriate therapy may be initiated earlier to enhance survival in these immunocompromised patient populations.

[1]  M. Kollef,et al.  Secular Trends in Candidemia-Related Hospitalization in the United States, 2000–2005 , 2008, Infection Control & Hospital Epidemiology.

[2]  B. Spellberg,et al.  Recent advances in the management of mucormycosis: from bench to bedside. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Russell E. Lewis,et al.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. , 2005, The Journal of infectious diseases.

[4]  A. Chandraker,et al.  Invasive fungal infections and antifungal therapies in solid organ transplant recipients , 2007, Transplant international : official journal of the European Society for Organ Transplantation.

[5]  E. Anaissie,et al.  Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Boeckh,et al.  Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. , 2002, Blood.

[7]  M. Pfaller,et al.  Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem , 2007, Clinical Microbiology Reviews.

[8]  D. Kontoyiannis,et al.  Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  E. Anaissie,et al.  Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  J. Perfect,et al.  Voriconazole treatment for less-common, emerging, or refractory fungal infections. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  J. Fine,et al.  Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  D. Kontoyiannis,et al.  Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). , 2006, Haematologica.

[14]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[15]  N. Khardori Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET) , 2010 .

[16]  Nina Singh,et al.  Fungal infections in the recipients of solid organ transplantation. , 2003, Infectious disease clinics of North America.

[17]  J. Garbino,et al.  Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[18]  B. Plikaytis,et al.  Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  J. Gómez-Moreno,et al.  Infection in organ-transplant recipients. , 1998, The New England journal of medicine.

[20]  D. Ellis,et al.  Treatment of Scedosporiosis with Voriconazole: Clinical Experience with 107 Patients , 2008, Antimicrobial Agents and Chemotherapy.

[21]  N. Milman,et al.  Aspergillus infection in lung transplant patients: incidence and prognosis , 2007, European Journal of Clinical Microbiology & Infectious Diseases.

[22]  J. Loeffler,et al.  Aspergillus PCR formidable challenges and progress. , 2009, Medical mycology.

[23]  D. Dunn,et al.  Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. , 1996, Journal of the American College of Surgeons.

[24]  R. Wenzel,et al.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  L. Pagano,et al.  Scedosporiosis in patients with acute leukemia: a retrospective multicenter report , 2008, Haematologica.

[26]  Ronald N. Jones,et al.  Candida Bloodstream Infections: Comparison of Species Distributions and Antifungal Resistance Patterns in Community-Onset and Nosocomial Isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009 , 2010, Antimicrobial Agents and Chemotherapy.

[27]  Thomas J Walsh,et al.  Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  M. Mardani,et al.  Outcome Determinants of Fusariosis in a Tertiary Care Cancer Center: The Impact of Neutrophil Recovery , 2004, Leukemia & lymphoma.

[29]  K. Gupta,et al.  Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. , 2009, The Journal of infectious diseases.

[30]  Lawrence Corey,et al.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  P. Carver,et al.  Antifungal prophylaxis in liver transplant recipients , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[33]  D. Mannino,et al.  The epidemiology of sepsis in the United States from 1979 through 2000. , 2003, The New England journal of medicine.

[34]  N. Funata,et al.  Reappraisal of the serum (1-->3)-beta-D-glucan assay for the diagnosis of invasive fungal infections--a study based on autopsy cases from 6 years. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.